ES2634008T3 - Agente terapéutico para la artrosis - Google Patents
Agente terapéutico para la artrosis Download PDFInfo
- Publication number
- ES2634008T3 ES2634008T3 ES12847890.6T ES12847890T ES2634008T3 ES 2634008 T3 ES2634008 T3 ES 2634008T3 ES 12847890 T ES12847890 T ES 12847890T ES 2634008 T3 ES2634008 T3 ES 2634008T3
- Authority
- ES
- Spain
- Prior art keywords
- osteoarthritis
- carbon atoms
- linear
- group
- cpa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000008482 osteoarthritis Diseases 0.000 title abstract description 7
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 150000001340 alkali metals Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 23
- 229920002674 hyaluronan Polymers 0.000 description 23
- 229960003160 hyaluronic acid Drugs 0.000 description 23
- 108090000790 Enzymes Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000001612 chondrocyte Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 102000003918 Hyaluronan Synthases Human genes 0.000 description 3
- 108090000320 Hyaluronan Synthases Proteins 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 238000005115 demineralization Methods 0.000 description 2
- 230000002328 demineralizing effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101000962530 Homo sapiens Hyaluronidase-1 Proteins 0.000 description 1
- 101000962526 Homo sapiens Hyaluronidase-2 Proteins 0.000 description 1
- 101001041128 Homo sapiens Hyaluronidase-3 Proteins 0.000 description 1
- 102100039283 Hyaluronidase-1 Human genes 0.000 description 1
- 102100039285 Hyaluronidase-2 Human genes 0.000 description 1
- 102100021082 Hyaluronidase-3 Human genes 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 210000002184 nasal cartilage Anatomy 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011247047 | 2011-11-11 | ||
| JP2011247047 | 2011-11-11 | ||
| PCT/JP2012/076478 WO2013069404A1 (ja) | 2011-11-11 | 2012-10-12 | 関節症治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2634008T3 true ES2634008T3 (es) | 2017-09-26 |
Family
ID=48289788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12847890.6T Active ES2634008T3 (es) | 2011-11-11 | 2012-10-12 | Agente terapéutico para la artrosis |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9085593B2 (https=) |
| EP (1) | EP2803359B1 (https=) |
| JP (1) | JP5465815B2 (https=) |
| KR (1) | KR101953181B1 (https=) |
| CN (1) | CN103906519B (https=) |
| AU (1) | AU2012337087B2 (https=) |
| BR (1) | BR112014011315B8 (https=) |
| CA (1) | CA2855660C (https=) |
| ES (1) | ES2634008T3 (https=) |
| IN (1) | IN2014CN04222A (https=) |
| MY (1) | MY168931A (https=) |
| PH (1) | PH12014501058B1 (https=) |
| RU (1) | RU2646457C2 (https=) |
| SG (1) | SG11201402226PA (https=) |
| WO (1) | WO2013069404A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3483169B1 (en) | 2014-08-12 | 2021-05-26 | Otsuka Chemical Co., Ltd. | Crystal of cyclic phosphonic acid sodium salt and method for manufacturing same |
| JP6727596B1 (ja) | 2019-11-22 | 2020-07-22 | 国立大学法人お茶の水女子大学 | カルバリゾホスファチジン酸 |
| JP7566783B2 (ja) | 2019-12-23 | 2024-10-15 | 大塚化学株式会社 | カルバ環状ホスファチジン酸化合物 |
| JP7736256B2 (ja) * | 2020-11-13 | 2025-09-09 | 株式会社マツモト交商 | 環状ホスファチジン酸含有組成物及び美容方法 |
| CN116710105A (zh) * | 2020-11-26 | 2023-09-05 | 山椒株式会社 | 肺纤维化治疗剂 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2700350B2 (ja) | 1990-04-20 | 1998-01-21 | 小糸工業株式会社 | 車両感知器 |
| JP3195833B2 (ja) | 1991-09-30 | 2001-08-06 | きみ子 室伏 | 新規生理活性物質及びその製造法 |
| JPH07149772A (ja) | 1993-11-26 | 1995-06-13 | Sagami Chem Res Center | タンパク質リン酸化酵素ｃの活性促進剤 |
| JPH07258278A (ja) | 1994-03-18 | 1995-10-09 | Sagami Chem Res Center | １−Ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするＤＮＡポリメラーゼαの阻害剤 |
| JPH0925235A (ja) | 1995-07-13 | 1997-01-28 | Sagami Chem Res Center | １−ｏ−アシルグリセロール−２，３−ホスフェート誘導体を有効成分とするがん転移抑制剤 |
| JP2001178489A (ja) | 1999-12-24 | 2001-07-03 | Kimiko Murofushi | 環状ホスファチジン酸の製造法 |
| JP4815063B2 (ja) * | 2001-04-13 | 2011-11-16 | きみ子 室伏 | 環状ホスファチジン酸を含むグリア細胞の増殖、分化及び／又は生存の促進のための薬剤 |
| JP4836345B2 (ja) * | 2001-04-13 | 2011-12-14 | きみ子 室伏 | 環状ホスファチジン酸誘導体を含む神経細胞の生存促進剤 |
| US20040214799A1 (en) * | 2001-05-21 | 2004-10-28 | Mutsuko Mukai | Cancerous metastasis inhibitors containing carbacyclic phosphatidic acid derivatives |
| JP4162927B2 (ja) | 2002-06-11 | 2008-10-08 | きみ子 室伏 | カルバ環状ホスファチジン酸誘導体 |
| RU2240131C1 (ru) * | 2003-04-04 | 2004-11-20 | Аладьев Сергей Иванович | Средство "артровит" для профилактики и лечения артритов и артрозов |
| CA2521189A1 (en) * | 2003-04-11 | 2004-10-28 | Gabor Tigyi | Lysophosphatidic acid analogs and inhibition of neointima formation |
| JP4873352B2 (ja) | 2005-02-16 | 2012-02-08 | シェーリング コーポレイション | Ｃｘｃｒ３アンタゴニスト活性を有する、複素環で置換されたピペラジン |
| EP2098237B1 (en) * | 2006-12-28 | 2012-08-29 | Ochanomizu University | Analgesic agent comprising cyclic phosphatidic acid derivative |
| JP2010189315A (ja) * | 2009-02-18 | 2010-09-02 | Unitika Ltd | 関節軟骨損傷治癒促進剤及びそれを含有する飲食品 |
-
2012
- 2012-10-12 JP JP2013542900A patent/JP5465815B2/ja active Active
- 2012-10-12 MY MYPI2014701211A patent/MY168931A/en unknown
- 2012-10-12 PH PH1/2014/501058A patent/PH12014501058B1/en unknown
- 2012-10-12 IN IN4222CHN2014 patent/IN2014CN04222A/en unknown
- 2012-10-12 AU AU2012337087A patent/AU2012337087B2/en active Active
- 2012-10-12 RU RU2014123690A patent/RU2646457C2/ru active
- 2012-10-12 BR BR112014011315A patent/BR112014011315B8/pt active IP Right Grant
- 2012-10-12 SG SG11201402226PA patent/SG11201402226PA/en unknown
- 2012-10-12 WO PCT/JP2012/076478 patent/WO2013069404A1/ja not_active Ceased
- 2012-10-12 ES ES12847890.6T patent/ES2634008T3/es active Active
- 2012-10-12 US US14/357,089 patent/US9085593B2/en active Active
- 2012-10-12 CN CN201280055135.7A patent/CN103906519B/zh active Active
- 2012-10-12 EP EP12847890.6A patent/EP2803359B1/en active Active
- 2012-10-12 KR KR1020147015608A patent/KR101953181B1/ko active Active
- 2012-10-12 CA CA2855660A patent/CA2855660C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103906519A (zh) | 2014-07-02 |
| BR112014011315A2 (pt) | 2017-05-09 |
| AU2012337087A1 (en) | 2014-06-05 |
| EP2803359A4 (en) | 2015-12-16 |
| BR112014011315B8 (pt) | 2020-09-15 |
| PH12014501058A1 (en) | 2014-06-23 |
| EP2803359B1 (en) | 2017-04-19 |
| NZ624870A (en) | 2016-01-29 |
| US20140309194A1 (en) | 2014-10-16 |
| HK1199406A1 (en) | 2015-07-03 |
| RU2646457C2 (ru) | 2018-03-05 |
| CN103906519B (zh) | 2017-10-10 |
| BR112014011315B1 (pt) | 2020-03-03 |
| IN2014CN04222A (https=) | 2015-07-17 |
| RU2014123690A (ru) | 2015-12-20 |
| CA2855660C (en) | 2019-04-16 |
| EP2803359A1 (en) | 2014-11-19 |
| SG11201402226PA (en) | 2014-10-30 |
| US9085593B2 (en) | 2015-07-21 |
| JPWO2013069404A1 (ja) | 2015-04-02 |
| AU2012337087B2 (en) | 2016-11-17 |
| WO2013069404A1 (ja) | 2013-05-16 |
| CA2855660A1 (en) | 2013-05-16 |
| MY168931A (en) | 2019-01-09 |
| KR20140098778A (ko) | 2014-08-08 |
| KR101953181B1 (ko) | 2019-02-28 |
| PH12014501058B1 (en) | 2019-11-08 |
| JP5465815B2 (ja) | 2014-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2634008T3 (es) | Agente terapéutico para la artrosis | |
| Zhang et al. | The use of type 1 collagen scaffold containing stromal cell-derived factor-1 to create a matrix environment conducive to partial-thickness cartilage defects repair | |
| Datta et al. | Effect of bone extracellular matrix synthesized in vitro on the osteoblastic differentiation of marrow stromal cells | |
| ES2710921T3 (es) | Composiciones para tratar y prevenir lesión y enfermedad tisular | |
| Bekkers et al. | One-stage focal cartilage defect treatment with bone marrow mononuclear cells and chondrocytes leads to better macroscopic cartilage regeneration compared to microfracture in goats | |
| ES2729115T3 (es) | Usos de la condroitina no sulfatada | |
| BRPI0709516A2 (pt) | um meio de cultura e um composto farmacêutico para regenerar tecido cartilaginoso, método, usos e produtos a ela relacionados | |
| Altan et al. | The effect of platelet-rich plasma on osteochondral defects treated with mosaicplasty | |
| Lohan et al. | Tenogenesis of decellularized porcine achilles tendon matrix reseeded with human tenocytes in the nude mice xenograft model | |
| ES2427730T3 (es) | Composición para el tratamiento de la artritis reumatoide | |
| Lim et al. | A decellularized scaffold derived from squid cranial cartilage for use in cartilage tissue engineering | |
| US20260083780A1 (en) | Complex for promoting cartilage differentiation comprising cartilage cell-free crush and stem cell and use thereof | |
| Van den Akker et al. | Development of a cyclic-inverso AHSG/Fetuin A-based peptide for inhibition of calcification in osteoarthritis | |
| Zhang et al. | Repair of sciatic nerve defects using tissue engineered nerves | |
| Ghosh et al. | Effects of spirulina in arsenic poisoning in the Black Bengal goat | |
| US8709401B2 (en) | Primed stem cells and uses thereof to treat inflammatory conditions in joints | |
| Frohbergh et al. | Acid ceramidase treatment enhances the outcome of autologous chondrocyte implantation in a rat osteochondral defect model | |
| ES2562217T3 (es) | Disacáridos para el tratamiento de tendones y ligamentos | |
| Pei et al. | Failure of xenoimplantation using porcine synovium‐derived stem cell‐based cartilage tissue constructs for the repair of rabbit osteochondral defects | |
| WO2018215684A1 (es) | Medios de cultivo con lisados plaquetarios | |
| Malinin et al. | Induction of regeneration of articular cartilage defects by freeze dried particulate cartilage allografts | |
| Shin et al. | The Protective Effect of Decellularized Extracellular Matrix in Osteoarthritis: An In Vitro and In Vivo Study in Rat Model | |
| Shahid et al. | Ameliorative Effect of Vitamin D on Articular Cartilage Thickness in Arthritic Rat Model | |
| Chetsawang | Amniotic Fluid-derived MSC Secretome Halts Action of IL-1β and TNF-α Through ERK/MAPK and Returns Cartilage Repair Under OA Inflammatory Stimuli | |
| Lopez Jimenez | Regeneration of Equine MSC-derived Cartilage: Efforts Towards Functional Tissue Engineering |